Skip to content

Clinical Study on the Experience-Based Formula of Professor Wang Shuchen for the Treatment of Stable Chronic Obstructive Pulmonary Disease (Lung-Kidney Deficiency with Phlegm and Blood Stasis Obstructing the Lung)

Clinical Study on the Experience-Based Formula of Professor Wang Shuchen for the Treatment of Stable Chronic Obstructive Pulmonary Disease (Lung-Kidney Deficiency with Phlegm and Blood Stasis Obstructing the Lung)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000791
Enrollment
Unknown
Registered
2025-04-21
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Control group:Placebo granules simulating the COPD experience-based formula + standard Western medicine treatment
Treatment group:COPD experience-based formula granules + standard Western medicine treatment

Sponsors

Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria for chronic obstructive pulmonary disease (COPD) in Western medicine. 2. Stable condition for the past four weeks with no acute exacerbations. 3. Diagnosed with lung-kidney deficiency and phlegm-blood stasis obstructing the lung syndrome based on Traditional Chinese Medicine (TCM) differentiation. 4. Aged 40–80 years with no gender restrictions. 5. Willing to comply with the physicians diagnosis and treatment plan and providing signed informed consent. Only patients meeting all the above criteria will be included in the study.

Exclusion criteria

Exclusion criteria: 1. Presence of severe primary diseases of the cardiovascular cerebrovascular hepatic renal gastrointestinal hematologic or endocrine systems. 2. Women who are pregnant breastfeeding or planning pregnancy within six months. 3. Abnormal liver or kidney function: serum creatinine (Scr) > 1.5 times the upper normal limit and/or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times the upper normal limit. 4. History of allergies or known hypersensitivity to the study medication. 5. History of psychiatric disorders intellectual disability mobility impairment or any condition that may affect informed consent validity. 6. Participation in other clinical trials within the past three months. 7. Other conditions deemed unsuitable for inclusion by the investigators.

Design outcomes

Primary

MeasureTime frame
COPD Assessment Test (CAT) score;

Secondary

MeasureTime frame
Pulmonary function test (PFT);Number of acute exacerbations;modified British medical research council;

Contacts

Public ContactCui Yun

Xiyuan Hospital China Academy of Chinese Medical Sciences

cui-yun@sohu.com13681575200

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026